

- 11:00 140. Effects of Combinations of HIV-1 Specific RT Inhibitors with Complementary Resistance Profiles on the Time and Type of Drug-Resistant HIV-1 Development. R. Pauwels, M.P. de Béthune, K. Andries, P. Stoffels, J. Desmyter, P.A.J. Janssen, and E. De Clercq. *Katholieke Universiteit Leuven, Leuven; and Janssen Research Foundation, Beerse, Belgium.*
- 11:15 141. Phosphorylation and Subcellular Distribution of HIV-1 MA Protein. A. Boukrinskaia, R. Lewis, and M. Stevenson. *The D.I. Ivanovsky Institute of Virology, Moscow, Russia; Eppley Research Institute, Omaha; and University of Nebraska Medical Center, Omaha, Nebraska, USA.*
- 11:30 142. Replication of HIV-1 and HSV-1 in Macrophages: Comparative Activity of Acyclic Nucleoside Phosphonates in the Presence or Absence of Cytokines Enhancers of Virus Replication. C.F. Perno, J. Balzarini, E. Balestra, S. Aquaro, G. Milanese, E. De Clercq, and R. Calio'. *University of Rome "Tor Vergata", Rome, Italy; and Katholieke Universiteit Leuven, Leuven, Belgium.*
- 11:45 143. Antiviral Drug Resistance Mutations in HIV-1 Reverse Transcriptase Occur in Specific RNA Structural Regions. E.W. Taylor, C.S. Ramanathan, R.M. Lloyd, Jr., and R.F. Schinazi. *The University of Georgia, Athens, GA; and Emory University and Veterans Administration Medical Center, Decatur, GA, USA.*

12:00 Lunch

Oral Session VII: Retrovirus Infections III

Chairpersons: J.C. Martin and J.L. Imbach

- 1:30pm 144. Identification of Distinct Subgroups of Nonnucleoside Reverse Transcriptase Inhibitors Defined by Cross-Resistance Phenotypes of Drug-Resistant Virus Isolates. R.W. Buckheit, Jr. and V. Fliakas-Boltz. *Southern Research Institute, Frederick Research Center, Frederick, MD, USA.*
- 1:45 145. Drug-Resistant HIV-1 Mutants May Undergo Further Mutations in the Reverse Transcriptase (RT) under Continuous Pressure of HIV-1-Specific RT Inhibitors. J. Balzarini, A. Karlsson, and E. De Clercq. *Katholieke Universiteit Leuven, Leuven, Belgium; and Karolinska Institute, Stockholm, Sweden.*
- 2:00 146. Drug-Induced Cell Mediated Mechanism Leading to Resistance of HIV to AZT. F. Dianzani, O. Turriziani, G. Antonelli, E. Riva, E. Simeoni, M. Cianfriglia, and A. Fattorossi. *University "La Sapienza", Rome; University of Pisa, Pisa; Istituto Superiore di Sanita', Rome; and Laboratory of Immunology D.A.S.R.S. Pratica di Mare, Rome, Italy.*

- 2:15 147. Boron Modified Peptide: a Novel Dissociative Inhibitor of HIV-1 Protease. A.D. Pivazyán and W.H. Prusoff. *Yale University, New Haven, CT, USA.*
- 2:30 148. Factors Other Than Reverse Transcriptase Contribute to Resistance of Feline Immunodeficiency Virus to Reverse Transcriptase-Targeted Antivirals. T.W. North, K.M. Remington, Y.-Q. Zhu, R.A. Smith, and D.G. McBroom. *University of Montana, Missoula, MT, USA.*
- 2:45 149. Long Term Suppression of Human Immunodeficiency Virus Type 1 Activity In Vitro by Guanosine/Thymidine Oligonucleotides (GTOs). R.F. Rando, J. Ojwang, A. Elbaggari, G.R. Reyes, K. Jayaraman, and M.S. McGrath. *Triplex Pharmaceutical Corporation, The Woodlands, TX; and University of California at San Francisco, San Francisco General Hospital, San Francisco, USA.*
- 3:00 150. Development of an In Vivo Model of HIV Latency and Activation. P.M. Feorino, S.T. Butera, J.R. Mead, T.M. Folks, and R.F. Schinazi. *VA Medical Center, Emory University, Decatur, GA; and Centers for Disease Control and Prevention, Atlanta, GA, USA.*
- 3:15 151. Use of Fluorescent Tracking Dye PKH26 to Follow the Fate of HIV-Infected Human PBMC in SCID Mice: An In Vivo Model for AIDS Drug Development. P.L. Black, D.D. Broud, O.L. Wood, G.P. Goldberg, and M.A. Ussery. *FDA, Rockville, MD, USA.*
- 3:30 152. HIV-Infected Hu-PBMC-SCID Mice as Model for Antiviral Drug Development. M.A. Ussery, D.D. Broud, O.L. Wood, and P.L. Black. *FDA, Rockville, MD, USA.*
- 3:45 153. Brain Delivery of 2'-F-ara-ddI by Utilizing Xanthine Oxidase Biotransformation System. C.K. Chu, T. Koudriakova, K. Shanmuganathan, L. Ni, F.D. Boudinot, J.M. Gallo, and R.F. Schinazi. *University of Georgia, Athens, GA; and Emory University School of Medicine, VAMC, Atlanta, GA, USA.*

Poster Session III: Hepadnavirus, Respiratory Virus, and Other Infections

4:30-6:30pm

154. Priming of Duck Hepatitis B Virus DNA Replication: A Viral Function Which is Refractory to Inhibition by Triphosphates of Dideoxynucleoside Analogs. K.A. Staschke, A.J. Schilke, and J.M. Colacino. *Lilly Research Laboratories, Indianapolis, IN, USA.*
155. Synthesis and Antiviral Activity of Novel Tricyclic Analogues of Acyclovir and Ganciclovir. B. Golankiewicz, T. Ostrowski, G. Andrei,